Persistent Genital Arousal Disorder (PGAD): Case report of long-term symptomatic management with electroconvulsive therapy

Journal of Sexual Medicine

Volumn 6, Issue 10, 2009, Pages 2901-2909

  Korda, Joanna B ^a,b   Pfaus, James G ^c   Kellner, Charles H ^d   Goldstein, Irwin ^e,f  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Department of Psychology ^*  (Canada)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e ALVARADO HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine release; Electroconvulsive therapy; Persistent genital arousal disorder; Persistent sexual arousal syndrome

Indexed keywords

AMFEBUTAMONE; BACLOFEN; FOLLITROPIN; LAMOTRIGINE; LEVOTHYROXINE; LUTEINIZING HORMONE; MAPROTILINE; NORTRIPTYLINE; PARACETAMOL; PAROXETINE; PHENYLEPHRINE; PRAMOCAINE; PRASTERONE; PROTRIPTYLINE; QUETIAPINE; TESTOSTERONE; VALPROIC ACID; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANDROGEN BLOOD LEVEL; ANDROGEN DEFICIENCY; ARTICLE; BIPOLAR DISORDER; CASE REPORT; COOLING; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MENOPAUSE; MICTURITION; ORGASM; PERSISTENT GENITAL AROUSAL DISORDER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; SEXUAL AROUSAL; SEXUAL AROUSAL DISORDER; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; CHEMICALLY INDUCED; COMPLICATION; MIDDLE AGED; PSYCHOMETRY; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TIME; WITHDRAWAL SYNDROME;

BIPOLAR DISORDER; DEPRESSION; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MIDDLE AGED; ORGASM; PAROXETINE; PSYCHOMETRICS; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 70649105714     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01421.x     Document Type: Article

References (60)

1. Amsterdam A, Abu-Rustum N, Carter J, Krychman M. Persistent sexual arousal syndrome associated with increased soy intake. J Sex Med 2005, 3:338-40.
2. Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, Graziottin A, Heiman JR, Laan E, Meston C, Schover L, van Lankveld J, Schultz WW. Revised definitions of women's sexual dysfunction. J Sex Med 2004, 1:40-8.
3. Bell C, Richardson D, Goldmeier D, Crowley T, Kocsis A, Hill S. Persistent sexual arousal in a women with associated cardiac defects and raised atrial natriuretic peptide. Int J STD AIDS 2007, 18:130-1.
4. Goldstein I, De EJB, Johnson J, Goldstein I, Meston C, Davis S, Traish A. Persistent sexual arousal syndrome and clitoral priapism. Women's sexual function and dysfunction: Study, diagnosis and treatment 2006, 674-85. In, eds., London, Taylor and Francis
5. Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: Classifications and definitions. J Sex Med 2007, 4:241-50.
6. Leiblum S, Brown C, Wan J, Rawlinson L. Persistent sexual arousal syndrome: A descriptive study. J Sex Med 2005, 2:331-7.
7. Leiblum S, Seehuus M, Goldmeier D, Brown C. Psychological, medical and pharmacological correlates of persistent genital arousal disorder. J Sex Med 2007, 4:1358-66.
8. Medina CA. Clitoral priapism: A rare condition presenting as vulvar pain. Obstet Gynecol 2002, 100:1089-91.
9. Goldmeier D, Leiblum S. Interaction of organic and psychological factors in persistent genital arousal disorder in women: A report of six cases. Int J STD AIDS 2008, 19:488-90.
10. Mahoney S, Zarate C. Persistent sexual arousal syndrome: A case report and review of the literature. J Sex Marital Ther 2007, 33:65-72.
11. Leiblum S, Goldmeier D. Persistent genital arousal disorder in women: Case reports of association with anti-depressant usage and withdrawal. J Sex Marital Ther 2008, 34:150-9.
12. Thorne C, Stuckey B. Pelvic congestion syndrome presenting as persistent genital arousal: A case report. J Sex Med 2008, 5:504-8.
13. Wylie K, Levin R, Hallman-Jones R, Goddard A. Sleep Exacerbation of persistent sexual arousal syndrome in a postmenopausal women. J Sex Med 2006, 3:296-302.
14. Yero SA, McKinney T, Petrides G, Goldstein I, Kellner CH. Successful use of electroconvulsive therapy in 2 cases of persistent sexual arousal syndrome and bipolar disorder. J ECT 2006, 22:274-5.
15. Waldinger MD, Gils APG, Ottervanger HP, Vandenbroucke WVA, Tavy DLJ. Persistent genital arousal disorder in 18 Dutch women: Part 1. MRI, EEG and TVUS investigation. J Sex Med 2009, 6:474-81.
16. Waldinger MD, Gils APG, Ottervanger HP, Vandenbroucke WVA, Tavy DLJ. Persistent genital arousal disorder in 18 Dutch women: Part 2. A syndrome clustered with restless legs and overactive bladder. J Sex Med 2009, 6:482-97.
17. Leiblum SR, Nathan SG. Persistent sexual arousal syndrome: A newly discovered pattern of female sexuality. J Sex Marital Ther 2001, 27:365-80.
18. Leiblum SR, Chivers ML. Normal and persistent genital arousal in women: New perspectives. J Sex Marital Ther 2007, 33:357-73.
19. Leiblum S, Seehuus M, Brown C. Persistent genital arousal: Disordered or normative aspect of female sexual response?. J Sex Med 2007, 4:680-7.
20. Goldmeier D, Leiblum SR. Persistent genital arousal in women-A new syndrome entity. Int J STD AIDS 2006, 17:215-6.
21. Hiller J, Hekster B. Couple therapy and cognitive behavioural techniques for persistent sexual arousal syndrome. Sex Relat Ther 2007, 22:91-6.
22. Bancroft J. Central inhibition of sexual response in the male: A theoretical perspective. Neurosci Biobehav Rev 1999, 23:763-84.
23. Pfaus JG. Pathways of sexual desire. J Sex Med 2009, 6:1506-33.
24. Pfaus JG, Damsma G, Wenkstern D, Fibiger HC. Sexual activity increases dopamine transmission in the nucleus accumbens and striatum of female rats. Brain Res 1995, 693:21-30.
25. Giuliano F, Rampin O, Allard J. Neurophysiology and pharmacology of female genital sexual response. J Sex Marital Ther 2002, 28:101-21.
26. Clayton AH. Epidemiology and neurobiology of female sexual dysfunction. J Sex Med 2007, 4(4):260-8. suppl
27. Fulford AJ, Marsden CA. An intact dopaminergic system is required for context-conditioned release of 5-HT in the nucleus accumbens of postweaning isolation-reared rats. Neuroscience 2007, 149:392-400.
28. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006, 3:628-38.
29. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA 2004, 101:10201-4.
30. Pfaus J, Giuliano F, Gelez H. Bremelanotide: An overview of preclinical CNS effects on female sexual function. J Sex Med 2007, 4(4):269-79. suppl
31. Hull EM, Lorrain DS, Du J, Matuszewich L, Lumley LA, Putnam SK, Moses J. Hormone-neurotransmitter interactions in the control of sexual behavior. Behav Brain Res 1999, 105:105-16.
32. Berk M, Dodd S, Kauer-Sant'anna M, Malhi GS, Bourin M, Kapczinski F, Norman T. Dopamine dysregulation syndrome: Implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007, 434:41-9.
33. Jacobs D, Silverstone T. Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 1986, 16:323-9.
34. Frey BN, Andreazza AC, Ceresér KM, Martins MR, Valvassori SS, Réus GZ, Quevedo J, Kapczinski F. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 2006, 79:281-6.
35. Abler B, Greenhouse I, Ongur D, Walter H, Heckers S. Abnormal reward system activation in mania. Neuropsychopharmacology 2008, 33:2217-27.
36. Nolen WA. Dopamine and mania. The effects of trans- and cis-clopenthixol in a double-blind pilot study. J Affect Disord 1983, 5:91-6.
37. van Praag HM, Korf J. Central monoamine deficiency in depressions: Causative of secondary phenomenon?. Pharmakopsychiatr Neuropsychopharmakol 1975, 8:322-6.
38. Cerullo MA, Strakowski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Subst Abuse Treat Prev Policy 2007, 2:29.
39. Shirayama Y, Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr Neuropharmacol 2006, 4:277-91.
40. Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. Am Fam Physician 2006, 74:449-56.
41. Korda JB, Pfaus JG, Goldstein I. Persistent Genital Arousal Disorder (PGAD): A case report in a woman with lifelong PGAD where serendipitous administration of varenicline tartrate resulted in symptomatic improvement. J Sex Med 2009, 6:1479-86.
42. Giuliano F, Allard J, Compagnie S, Alexandre L, Droupy S, Bernabe J. Vaginal physiological changes in a model of sexual arousal in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 2001, 281:R140-9.
43. Giuliano F, Rampin O, Allard J. Neurophysiology and pharmacology of female genital sexual response. J Sex Marital Ther 2002, 28(1):101-21. suppl
44. Caputi L, Hainsworth A, Guatteo E, Tozzi A, Stefani A, Spadoni F, Leach M, Bernardi G, Mercuri NB. Actions of the sodium channel inhibitor 202W94 on rat midbrain dopaminergic neurons. Synapse 2003, 48:123-30.
45. Pandya M, Pozuelo L, Malone D. Electroconvulsive therapy: What the internist needs to know. Cleve Clin J Med 2007, 74:679-85.
46. MacQueen G, Parkin C, Marriott M, Bégin H, Hasey G. The long-term impact of treatment with electroconvulsive therapy on discrete memory systems in patients with bipolar disorder. J Psychiatry Neurosci 2007, 32:241-9.
47. Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. Lancet 2003, 361:799-808. UK ECT Review Group
48. Abrams R, Essman WB, Taylor MA, Fink M. Concentration of 5-hydroxyindoleacetic acid, homovanillic acid, and tryptophan in the cerebrospinal fluid of depressed patients before and after ECT. Biol Psychiatry 1976, 11:85-90.
49. Devanand DP, Bowers MB, Hoffman FJ, Sackeim HA. Acute and subacute effects of ECT on plasma HVA, MHPG, and prolactin. Biol Psychiatry 1989, 26:408-12.
50. Okamoto T, Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Inoue Y, Ueda N, Nakamura J. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1185-90.
51. Glue P, Costello MJ, Pert A, Mele A, Nutt DJ. Regional neurotransmitter responses after acute and chronic electroconvulsive shock. Psychopharmacology (Berl) 1990, 100:60-5.
52. Grønli O, Stensland GO, Wynn R, Olstad R. Neurotrophic factors in serum following ECT: A pilot study. World J Biol Psychiatry 2007, 21:1-7.
53. Okamoto T, Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Inoue Y, Ueda N, Nakamura J. Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: A pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1185-90.
54. Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, Ramanujam S, Soekadar S, Demosthenous M, Regenold WT. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: A pilot study in patients with major depression. J Clin Psychiatry 2007, 68:512-7.
55. Cupello A, Bandini F, Albano C, Favale E, Marchese R, Scarrone S, Trompetto C. Catatonic features in major depression relieved by electroconvulsive treatment: Parallel evaluation of the status of platelet serotonin transporter. Int J Neurosci 2008, 118:1460-6.
56. Gur E, Dremencov E, Garcia F, Van de Kar LD, Lerer B, Newman ME. Functional effects of chronic electroconvulsive shock on serotonergic 5-HT(1A) and 5-HT(1B) receptor activity in rat hippocampus and hypothalamus. Brain Res 2002, 952:52-60.
57. Palmio J, Huuhka M, Saransaari P, Oja SS, Peltola J, Leinonen E, Suhonen J, Keränen T. Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatry Res 2005, 137:183-90.
58. Holaday JW, Tortella FC, Meyerhoff JL, Belenky GL, Hitzemann RJ. Electroconvulsive shock activates endogenous opioid systems: Behavioral and biochemical correlates. Ann N Y Acad Sci 1986, 467:249-55.
59. Wasan AD, Artin K, Clark MR. A case-matching study of the analgesic properties of electroconvulsive therapy. Pain Med 2004, 5:50-8.
60. Prudic J, Fitzsimons L, Nobler MS, Sackeim HA. Naloxone in the prevention of the adverse cognitive effects of ECT: A within-subject, placebo controlled study. Neuropsychopharmacology 1999, 21:285-93.